Updated at 11:16 p.m. ET
The Food and Drug Administration is cautioning the public about the reliability of a widely used rapid test for the coronavirus. The test, made by Abbott Laboratories, has been linked with inaccurate results which could falsely reassure patients that they are not infected with the virus.
The Trump Administration has promoted the test as a key factor in controlling the epidemic in the U.S. and is used for the daily testing that is going on at the White House.
As first reported on NPR, as many as 15 to 20 out of every 100 tests may produce falsely negative results. A subsequent study released this week indicated that the test could be missing as many as 48 percent of infections.
The FDA issued the alert on the Abbott test "in the spirit of transparency," and said in a press release, it's investigating whether the false-negative results could be connected to the type of swab used during the rapid test, or the material the samples are being stored in when they're transported.
It also cautions that "any negative test results that are not consistent with a patient's clinical signs and symptoms or necessary for patient management should be confirmed with another test."
"We are still evaluating the information about inaccurate results and are in direct communications with Abbott about this important issue," said Tim Stenzel, director of the FDA's Office of In Vitro Diagnostics and Radiological Health. "We will continue to study the data available and are working with the company to create additional mechanisms for studying the test.
The Abbott rapid test can still be used to identify positive COVID-19 cases, according to Stenzel, though negative results may need to go through a secondary process to be confirmed.
The FDA has received 15 "adverse event reports" about the test indicating patients are receiving inaccurate results, according to the press release.
The FDA will continue to monitor data on the test and work with Abbott, which has agreed to conduct post-market studies on their rapid test. The studies will include at minimum 150 people who have previously tested positive for coronavirus, and take place in clinical settings, the FDA release said.
Abbot's share price dropped more than 3 percent during after-hours trading on Thursday. (Abbott Laboratories is among NPR's financial supporters.)
The company told NPR in late April that any problems with the test could stem from samples being stored in a special solution known as viral transport media before being tested, instead of being inserted directly into the company's testing machine. As a result, the company recently instructed users to avoid using the solution and to only test samples put directly into the machine.
In addition, Abbot has continued to defend the accuracy of the test, and pointed to other studies that have found it is as accurate as any other tests being used.
Precise, timely testing has been a major challenge in the coronavirus pandemic. Beyond issues with accuracy of rapid tests, there have also been issues certifying antibody tests — those that can detect if someone has been infected with COVID-19 in the past.
Copyright 2020 NPR. To see more, visit https://www.npr.org.